Chinese clinical-stage biopharmaceutical firm VivaVision Biotech Inc. has completed a 300 million yuan ($46 million) Series D round led by Sequoia Capital China.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
